Clinical Trial Update: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of erlotinib hydrochloride and cetuximab in patients with advanced cancers including head and neck, non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Colon Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Rectal Cancer
• Tongue Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Status: COMPLETED